{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-037371","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-09-23T10:03:20+00:00","discovered_at":"2026-09-23T10:05:06.649382+00:00","generated_at":"2026-09-23T10:05:19.095922+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ionis and Roche report positive Phase 3 interim data for sefaxersen in IgAN","bullets":["Phase 3 IMAgINATION met primary endpoint: sefaxersen reduced proteinuria (UPCR) vs placebo at 37 weeks, statistically significant and clinically meaningful.","Safety consistent with prior data, no new signals; study continues blinded to week 105 eGFR assessment.","459 patients enrolled, randomized 1:1; sefaxersen is once-monthly subcutaneous self-administered injection.","Interim data to be presented at medical meeting and shared with health authorities to expedite potential approval.","Ionis eligible for regulatory/sales milestones and tiered royalties on net sales from Roche license."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-037371","json":"https://secwatch.observer/filing/0001140361-26-037371.json","markdown":"https://secwatch.observer/filing/0001140361-26-037371.md","text":"https://secwatch.observer/filing/0001140361-26-037371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/0001140361-26-037371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/ef20082626_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T10:05:19.095922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}